In this episode, we speak with Mathai Mammen, the CEO of Parabilis Medicines, and a former R&D leader at J&J and Merck, about drugging the previously undruggable 80% of disease-causing proteins inside cells. He explains how their Helicon platform uses AI and unnatural amino acids to create peptides that access intracellular targets unreachable by other drugs. We discuss their lead program’s remarkable clinical results in desmoid tumors, their pipeline in prostate cancer, and why now is the perfect time for innovators to aim high and do something revolutionary in healthcare.